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The need for a rotavirus vaccine in India is based on the enormous burden associated with the 1100,000
deaths due to rotavirus diarrhea that occur annually among Indian children. Two rotavirus strains identified
during nosocomial outbreaks of rotavirus infection in New Delhi and Bangalore, India, more than a decade
ago are being developed as live oral vaccines. Infected newborns had no symptoms, shed virus for up to 2
weeks after infection, mounted a robust immune response, and demonstrated protection against severe ro-
tavirus diarrhea after reinfection. The 2 strains are naturally occurring bovine-human reassortants. The New
Delhi strain, 116E, is characterized as having a P[11],G9 genotype, and the Bangalore strain, I321, is char-
acterized as having a P[11],G10 genotype. The strains have been prepared as pilot lots for clinical trials to be
conducted in New Delhi. This unique project, which is developing a new rotavirus vaccine in India with the
use of Indian strains, an Indian manufacturer, and an Indian clinical development program, aims to expedite
introduction of rotavirus vaccines in India.
In India, diarrhea is a leading cause of illness and death
among children !5 years old. Efforts to decrease the
number of cases of diarrheal disease through programs
of home-based treatment with oral rehydration ther-
apy and improvements in water and sanitation, al-
though partially successful, have so far fallen short of
their goals. This may be due, in part, to the observations
that (1) ∼25%–35% of childhood hospitalizations for
severe diarrhea result from infection with rotavirus, a
pathogen that is not affected by improvements in clean
water and hygiene, and (2) attempts to use rehydration
therapy for patients with rotavirus are most likely to
fail because vomiting, which is a main cause of treat-
ment failure, is also a common presenting symptom of
rotavirus gastroenteritis [1].
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Because every child in India will become infected
with rotavirus during the first few years of life, it is
estimated that 25 million children born in India each
year will experience ∼20 million episodes of rotavirus
diarrhea by 5 years of age, with ∼400,000 hospitaliza-
tions and 100,000 deaths resulting from these episodes
[2]. The 100,000 deaths due to rotavirus diarrhea rep-
resent ∼5% of all deaths occurring among children !5
years of age and ∼1 death among every 250 children
born. The development and introduction of a rotavirus
vaccine have become a national priority. The national
immunization program in India currently reaches 170%
of all children with their first vaccination. If a rotavirus
vaccine could be introduced into the routine schedule
of childhood immunization through the expanded pro-
gram of immunization, it could have an immediate effect
by reducing, within 2 or 3 years, the burden associated
with diarrhea, the number of diarrhea-related hospital-
izations, and, perhaps, the number of deaths due to di-
arrhea. Few other health interventions could have such
an immediate and visible effect.
The process for making a rotavirus vaccine uses tech-
nology appropriate for manufacturers in the develop-
ing world. All rotavirus vaccines developed to date have
been based on live rotavirus strains that have been iso-
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lated from humans or animals and that have been adapted to
cell culture, formulated for oral delivery, and tested in clinical
trials. Both monovalent human strains and multivalent animal-
based strains have demonstrated efficacy as candidate vaccines.
Two vaccines, Rotarix (GlaxoSmithKline) and Rotateq (Merck),
are the most advanced in their development; RotaShield (Wy-
eth-Ayerst) was licensed but then was withdrawn. Rotarix is
derived from a single serotype G1 human rotavirus strain atten-
uated by multiple passages in cell culture. Like natural infection
in children, Rotarix appears to induce cross-protection against
G9 strains; this finding suggests that Rotarix will be suitable
against a range of the common serotypes [3]. Vaccines derived
from animal strains of simian (RotaShield) or bovine (Rotateq)
origin appear to require a combination of reassortant strains
to ensure adequate protection against the common serotypes
[4], although candidate monovalent vaccines developed from
a single animal strain have been effective in some settings [5].
In the absence of good correlates of protection, field trials
remain the only method by which to evaluate the efficacy of a
new vaccine, a process that can take several years to complete.
During the past 2 decades, much experience has been gained
in conducting clinical trials of various candidate rotavirus vac-
cines. The trials have often been successful, and, in a trial per-
formed in Finland (the one country where nearly every candidate
vaccine has been tested), all live oral vaccines tested to date, with
the exception of one, demonstrated 180% efficacy against se-
vere disease [6].
Most vaccines currently administered to Indian children and
much of the childhood vaccines tendered by the United Na-
tions Children’s Fund are manufactured in India. New vaccines
against hepatitis B virus and Haemophilus influenzae type b,
produced by multinational vaccine manufacturers, have been
introduced into the market in the private sector; however, the
fact that uptake of these vaccines has been slow had raised clear
questions of equity. Children with the heaviest burden of dis-
ease, the highest associated mortality rate, and the least access
to care are the last to receive benefit from new vaccines. As
Indian manufacturers have begun producing vaccines against
hepatitis B virus, the supply has increased, the associated cost
has plummeted, and the vaccine has finally become part of the
programs of routine childhood immunization in several states.
If a rotavirus vaccine were developed and manufactured in
India, it might also be introduced directly into a program of
routine childhood immunization. This could lead to an earlier,
positive benefit with regard to a reduction in the number of
cases of disease among children who are at greatest risk for
hospitalization or death associated with diarrhea. In the present
study, we review previously reported information on the iso-
lation of 2 naturally attenuated rotavirus strains from Indian
newborns, describe the rationale for using these strains to de-
velop candidate vaccines, present new data on the early clinical
testing of these candidate vaccines, and outline plans for further
evaluation of these vaccines in India.
ORIGIN AND PROPERTIES OF THE INDIAN
NEONATAL ROTAVIRUS STRAINS
In 1985, an “outbreak” of asymptomatic rotavirus infections
was observed in the newborn unit of the All India Institute of
Medical Sciences (AIIMS) in New Delhi, India; this outbreak
was similar to that previously observed by Bishop et al. [7] in
Australia. The infections were clearly nosocomial; the rate of
infection was lowest for newborns discharged after 1 day of
hospitalization, and it reached 50% for newborns hospitalized
for 3 days and 75% for newborns hospitalized for a full week
[8, 9]. None of these newborns developed symptoms, and the
source of the infection was never determined. Among multiple
isolates, all 11 gene segments of the neonatal strains appeared
to be identical on the basis of the results of electrophoresis,
confirming a point-source nosocomial infection with a single
strain at AIIMS [9]. We never identified the source of infection,
but the outbreak of infection among newborns persisted for
several years.
When we attempted, by means of reverse-transcription poly-
merase chain reaction (PCR), to type the strain (now known
as “strain 116E”) that was the source of this outbreak, we were,
at first, unsuccessful. A major effort to decipher the identity
of these neonatal strains from New Delhi by means of sequence
analysis led to clarification of the problem: the sequence of the
VP7 gene was homologous to G9, a rare strain that, at the time,
had been seen only twice previously in children in Philadelphia
and Japan [10, 11]. The sequence of the VP4 gene was ho-
mologous to P[11], a genotype commonly found in cattle [12].
Strain 116E appeared to be a natural bovine-human reassortant
typed as P[11],G9. We then performed genogrouping to identify
the origin of the different gene segments in the new strain.
Strain 116E was a human G9 strain into which a single bovine
VP4 gene segment had been introduced.
The finding of a bovine-human reassortant added fuel to the
argument that reassortment between animal and human strains
was a plausible mechanism for the evolution of rotaviruses in
nature. Furthermore, because mothers would not be expected to
have antibodies to bovine strains, the presence of a bovine outer
capsid gene could explain why the strain replicated so well in
the infant gut. The infants mounted a readily detectable immune
response to rotavirus in their serum and saliva, suggesting that
their infections might protect against severe disease after rein-
fection [13]. Moreover, although rotavirus infection rarely occurs
among infants during the first few months of life, these infants
shed virus in their stools for up to 2 weeks after infection.
A study conducted by researchers in Bangalore, India, and
at Stanford University (Palo Alto, CA) followed a similar pat-
tern of discovery [14]. A nosocomial outbreak of infection at
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Figure 1. Gene origin of rotavirus vaccine strains. Shaded bars, genes of human origin; unshaded bars, genes of bovine origin. GSK, GlaxoSmithKline;
WC3, bovine rotavirus strain; WC3  D, bovine-human reassortant strain.
a maternity center in Bangalore led to the identification among
neonates of another “outbreak” due to a strain (known as “strain
I321”) that was also a bovine-human reassortant strain. Unlike
strain 116E, strain I321 had a base of 9 bovine gene segments,
and only gene segments 5 and 7, which encoded nonstructural
proteins 1 and 3, were of human origin [15]. A strain with the
same G and P characteristics as strain I321 has emerged as a
cause of diarrhea in children in Vellore, India; however, it is
unclear whether this virulent strain is identical to the original
neonatal isolate [16].
These 2 Indian neonatal strains have interesting differences
in their genomic structure (figure 1). Strain 116E is primarily
a human strain with a single bovine VP4 gene, making it similar
to the human vaccine strain being developed by GlaxoSmith-
Kline. The difference lies in its bovine VP4 gene, which may
improve its ability to colonize the infant gut in the presence
of maternal antibody and to induce an immune response. Pre-
sumably, the bovine gene is responsible, at least in part, for
attenuation. The I321 strain is composed primarily of bovine
genes and has only 2 segments that are of human origin, making
it more similar to the strain used in the Merck vaccine but
without the serotype-specific gene products.
RATIONALE FOR DEVELOPING CANDIDATE
ROTAVIRUS VACCINES BASED ON INDIAN
NEONATAL STRAINS
The ability of these rotavirus strains to replicate in infected
newborns without causing disease in the presence of high titers
of maternal antibody suggested that the strains were unusu-
al and, perhaps, naturally attenuated. Our research to explore
their potential as vaccine candidates went in several directions.
We first followed a cohort of infants with or without doc-
umented neonatal infection with strain 116E, to determine
whether these infants were indeed protected against rotavirus
diarrhea after reinfection [17]. This study demonstrated that
neonatal rotavirus infections occurred in 60% of newborns by
day 4 of life and that they conferred protection against rotavirus
diarrhea at a level similar to that observed by Bishop et al. [7]
in Australia. The 148 children who had a neonatal infection
experienced 0.23 episode of rotavirus diarrhea/child-year, com-
pared with 0.42 episode/child-year for the 56 children without
a neonatal infection. During the follow-up, approximately one-
third of the control subjects (i.e., infants who had not been
infected in the newborn unit) developed a 4-fold increase in
antibodies to rotavirus, indicating either a neonatal infection
that had been missed or an infection that occurred by 3 months
of age. Nonetheless, the data supported a protective role for
neonatal infection against subsequent and more-severe disease.
We then tried to determine whether this neonatal strain was
circulating in the community and was causing disease in older
children [18]. A survey of strains from around India failed to
identify this strain in children with diarrhea, but it found that
other serotype G9 strains were the most common rotavirus
strains detected in children with diarrhea in India. Since then,
G9 strains have emerged as new strains in the United States
and many other countries [19–22].
A recent 2-year follow-up study of a cohort of infants who
had been infected with I321 rotaviruses during the first 2 weeks
of life suggested that this group of infants was similarly protected
against disease [23]. One (2%) of 44 neonates infected with strain
I321 developed rotavirus diarrhea, compared with 11 (39%) of
28 neonates who were not infected with strain I321. A significant
decrease in the number of rotavirus infection–associated admis-
sions to the hospital was noted in parallel with a high (i.e., 25%–
50%) rate of asymptomatic neonatal infections. Collectively, these
findings suggested that asymptomatic neonatal infections with
these rotavirus strains are common in Indian infants and that
they confer protection against symptomatic rotavirus disease dur-
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Table 1. Comparison of Indian neonatal rotavirus strains.
Characteristic New Delhi strain 116E Bangalore strain I321
Origin All India Institute of Medical Sciences, New
Delhi, India, 1985
Indian Institute of Science, Bangalore, India,
1988–1991
Type P8[11],G9 P8[11],G10
Reassortment Human rotavirus with a single bovine gene (VP4) Bovine rotavirus with 2 human genes encoding
NSP1 and NSP3
Passage history Two passages in primary AGMK cells Two passages in primary AGMK cells
⇓ ⇓
Seven passages in Ma104 cells Eight passages in Ma104 cells
⇓ ⇓
Ten passages in SpAGMK cells Eight passages in SpAGMK cells
Subjects in US clinical studies, no.
Adults 10 10
Children 10 10
NOTE. AGMK, African green monkey kidney; NSP1, nonstructural protein 1; NSP3, nonstructural protein 3; SpAGMK, specially passaged AGMK.
ing the first 2 years of life, prompting us to develop candidate
vaccines based on these strains. All stages of development of
these vaccine candidates have been approved by the ethical review
committees at each of the collaborating institutions.
PROGRESS WITH VACCINE DEVELOPMENT
AND EARLY CLINICAL TESTING
The 2 Indian neonatal strains each appeared to be attractive as
future candidate rotavirus vaccines, and we had no basis, a priori,
to decide that one strain would prove to be better than the other
(table 1). The strains colonized the infant gut extremely well,
perhaps because maternal antibody does not have neutralizing
activity against this bovine outer capsid VP4. They caused no
disease after infection, were shed for 11 week (which induced a
robust immune response despite the presence of maternal an-
tibody), and were each associated with protection against disease
after reinfection.
Both strains were prepared as pilot vaccine lots for challenge
studies involving humans. For the I321 strain, the virus was
adapted to growth in cell culture by 2 passages in primary
African green monkey kidney (AGMK) cells, followed by 3
passages in MA104 cells. The virus was then plaque purified 3
times in MA104 cells, and a final plaque was used to infect
another flask of MA104 cells. After 1 more passage in these
cells to make a large preparation, the virus was frozen at70C
in aliquots and was stored. This virus went through 10 passages,
including the plaque purification steps. In 1996, these strains
were prepared as pilot vaccine lots at Flow Laboratories (L.
Potash, personal communication). The pilot lots were prepared
by using serially passaged AGMK cells. The final preparations
at passage 19 were thoroughly tested for use in humans and
were approved for clinical studies.
Two phase 1 clinical trials were initiated in the Vaccine Trial
and Evaluation Unit at the Cincinnati Children’s Hospital (Cin-
cinnati, OH), beginning with safety studies involving adults
and seropositive children (age, 2–12 years). Both studies were
randomized placebo-controlled trials. In each, stool specimens
were obtained to determine levels of virus excretion, and serum
samples were analyzed to determine changes in rotavirus an-
tibody titers. In the initial study, 30 adults with antibody to
rotavirus were equally divided into 3 groups of the same size
to receive a single oral dose of ffu of strain I321, strain510
116E, or a placebo after stomach acids were buffered. No vac-
cine recipient shed detectable levels of rotavirus, and, in these
seropositive adults, the vaccines were poorly immunogenic.
Only 2 subjects had a 4-fold increase in antibody titer, and
both received the 116E strain. Side effects were rare and mild,
although 2 subjects who received strain 116E developed mild
diarrhea for 1 day.
In the second study, 30 healthy children aged 2–12 years who
had rotavirus antibody received either the 116E or I321 vaccine
( ffu) or placebo after stomach acids were buffered. One510
vaccine recipient shed detectable levels of rotavirus, and 4 had
seroconversion; all had received strain 116E. Side effects were
rare and mild; no subject developed diarrhea or vomiting, but,
22 days after immunization, 1 recipient of strain 116E who did
not shed rotavirus or who did not experience seroconversion
developed ileus that was thought to be unrelated to the vaccine.
Both vaccines appeared to be attenuated, compared with
wild-type strains. They replicated poorly in adults and children
with preexisting immunity to rotavirus, and they appeared to
be safe. The 116E strain replicated somewhat more efficiently
and therefore was more immunogenic than the I321 strain.
PLANNED STUDIES IN INDIA
Further clinical studies are under development in India and will
progress through safety trials involving adults, children, and in-
fants. The safety trials involving infants will be the first to de-
termine whether these neonatal strains that were so successful
in infecting newborns at AIIMS and in Bangalore will continue
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to be avirulent and highly infectious and whether they will
induce both shedding and a good serum immune response after
administration of a single dose. Proof of the efficacy of these
strains will require several years of further testing.
One additional improvement in this candidate vaccine has
been the adaptation to growth in Vero cells, a cell line more
commonly used and widely available as a vaccine substrate.
Once pilot lots of these candidate vaccines have been prepared
at Bharat Biotech in Hyderabad, India, and have been approved
for use in humans by the Drug Controller General of India,
we anticipate a series of phase 1 and bridging studies that will
ultimately lead to a clinical trial of the use of at least 1 of these
preparations for Indian children.
DISCUSSION
This project is an alternative approach for the development of
vaccines to ensure the survival of children in developing coun-
tries. A great impetus to push this effort forward was the un-
timely withdrawal of RotaShield from the market as the result
of a detectable risk of intussusception developing in the 2 weeks
after vaccination. At the time of its withdrawal, RotaShield was
undergoing a clinical trial in New Delhi. It was hoped that a
successful trial outcome would lead to rapid introduction of
the vaccine. Indian authorities had been primed to consider
the need for the vaccine, to permit the importation of Rota-
Shield, and to approve its testing under the auspices of the
World Health Organization. Although concerns about the safety
of RotaShield in the United States led to its withdrawal, in
India, the high mortality associated with rotavirus disease, as
well as the rarity of the development of intussusception and
the low risk attributed to the vaccine, might still have made
this vaccine a lifesaver. However, it was considered politically
difficult and imprudent to consider the further development
and testing in India of a vaccine withdrawn from the US market.
These collaborative studies, conducted over more than a de-
cade by 2 independent groups of Indian and American re-
searchers, have identified several rotavirus strains isolated from
newborns without diarrhea that may be suitable as future can-
didate rotavirus vaccines. The strains are each bovine-human
reassortants that grow well in the newborn, do not cause di-
arrhea, are shed for a prolonged period, induce a good immune
response, and appear to protect infants against severe disease
after reinfection. Whether these strains will perform the same
after adaptation to growth in Vero cells remains to be deter-
mined. Clinical trials will be required to determine whether
these vaccines are safe and effective. Many hurdles lie ahead in
the development process.
These collaborations have changed our understanding of the
epidemiological profile of rotavirus infections in the develop-
ing world. First, attempts to characterize rotavirus strains from
many sites in India let us appreciate not only that the newborn
strains are really unique to newborns and are not found in
children with diarrhea but, also, that India has a greater di-
versity of strains in circulation than do most countries. For
example, our first small survey of 25 rotavirus specimens from
Lucknow, India, identified 8 different strains of rotavirus, more
than had ever been seen, at the time, in the rest of the world.
Mixed infections with 11 strain were common, as were in-
fections with bovine-human reassortants, a finding that en-
couraged us to think of genetic exchange between human and
bovine strains of the virus. Neonatal infections that are un-
common in industrialized countries appear to be common in
India and could provide another focus for routine immuni-
zation of infants at birth. Finally, our studies determined that
70%–80% of all rotavirus disease–associated hospitalizations in
India occur among children !1 year of age, which is earlier
than such hospitalizations occur among children in the United
States. This means that vaccines must be administered to chil-
dren before the age of 3 months if they are to be effective.
India has never developed, on its own, a new vaccine from
primary material obtained in India, with first manufacture in
India, and with the full clinical development program in an
Indian population. The rotavirus vaccine development program
is now funded by multiple donors within and outside India.
The goal remains to make a vaccine in India for India. The
consequences of this program could be the more rapid national
introduction of a vaccine for a disease that is already considered
to be a national priority, as well as a relationship with a local
producer committed to providing vaccine for the national im-
munization program at an affordable price.
There remain many hurdles in bringing this program to suc-
cessful completion, including the uncertainties associated with
determining whether the vaccine will have the efficacy anticipated
by the natural-history experiments. Many years of study and
research remain before the results of this experiment are known.
The goal of preventing 100,000 deaths/year in India is certainly
worth this sustained effort.
Acknowledgments
The 2 Indian neonatal candidate vaccine strains were each developed as
collaborations between Indian and US partners as part of the Indo-US
Vaccine Action Program, a bilateral program with its secretariat at the De-
partment of Biotechnology in India and at the National Institute of Allergy
and Infectious Diseases, National Institutes of Health, in the United States.
We are indebted to this program and its many members for their continuing
support, including, on the Indian side, T. S. Rao and Manju Sharma (De-
partment of Biotechnology) and Nirmal Ganguly (Indian Council of Med-
ical Research) and, on the US side, Kate Aultman, Leigh Sawyer, George
Curlin, and Carol Heilman (National Institutes of Health). We are indebted
to James Maynard, Jim Cheyne, David Alli, and, ultimately, to Bill and
Melinda Gates for their generous support.
Candidate Rotavirus Vaccines in India • JID 2005:192 (Suppl 1) • S35
References
1. Bahl R, Ray P, Subodh S, et al. Incidence of severe rotavirus diarrhea
in New Delhi, India, and G and P types of the infecting rotavirus
strains. J Infect Dis 2004; 192(Suppl 1):S114–9 (in this issue).
2. Jain V, Parashar UD, Glass RI, Bhan MK. Epidemiology of rotavirus
in India. Indian J Pediatr 2001; 68:855–62.
3. Perez-Schael I, Salinas B, Linhares AC, et al. Protective efficacy of an
oral human rotavirus (HRV) vaccine in Latin American infants. In:
Programs and abstracts of the 42nd Interscience Conference on An-
timicrobial Agents and Chemotherapy (San Diego). Washington, DC:
American Society for Microbiology, 2002.
4. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation
of rhesus rotavirus monovalent and tetravalent reassortant vaccines in
US children. JAMA 1995; 273:1191–6.
5. Vesikari T, Isolauri E, D’Hondt E, Delem A, Andre FE, Zissis G. Pro-
tection of infants against rotavirus diarrhoea by RIT 4237 attenuated
bovine rotavirus strain vaccine. Lancet 1984; 1:977–81.
6. Vesikari T, Joensuu J. Review of rotavirus vaccine trials in Finland. J
Infect Dis 1996; 174(Suppl 1):S81–7.
7. Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after
neonatal rotavirus infection: a prospective longitudinal study in young
children. N Engl J Med 1983; 309:72–6.
8. Jayashree S, Bhan MK, Raj P, et al. Neonatal rotavirus infection and
its relation to cord blood antibodies. Scand J Infect Dis 1988; 20:249–53.
9. Jayashree S, Bhan MK, Raj P, Kumar R. Naturally attenuated neonatal
rotavirus strain: a new vaccine candidate? In: Lasky L, ed. Technological
advances in vaccine development. New York: Alan R. Liss, 1988:175–81.
10. Das BK, Gentsch JR, Hoshino Y, et al. Characterization of the G se-
rotype and genogroup of New Delhi newborn rotavirus strain 116E.
Virology 1993; 197:99–107.
11. Das BK, Gentsch JR, Cicirello HG, et al. Characterization of rotavirus
strains from newborns in New Delhi, India. J Clin Microbiol 1994;
32:1820–2.
12. Gentsch JR, Das BK, Jiang B, Bhan MK, Glass RI. Similarity of the
VP4 protein of human rotavirus strain 116E to that of the bovine B223
strain. Virology 1993; 194:424–30.
13. Jayashree S, Bhan MK, Kumar R, Raj P, Glass R, Bhandari N. Serum
and salivary antibodies as indicators of rotavirus infection in neonates.
J Infect Dis 1988; 158:1117–20.
14. Sukumaran M, Gowda K, Maiya PP, et al. Exclusive asymptomatic
neonatal infections by human rotavirus strains having subgroup I spec-
ificity and “long” RNA electropherotype. Arch Virol 1992; 126:239–51.
15. Das M, Dunn SJ, Woode GN, Greenberg HB, Rao CD. Both surface
proteins (VP4 and VP7) of an asymptomatic neonatal rotavirus strain
(I321) have high levels of sequence identity with the homologous pro-
teins of a serotype 10 bovine rotavirus. Virology 1993; 194:374–9.
16. Iturriza Go´mara M, Kang G, Mammen A, et al. Characterization of
G10P[11] rotaviruses causing acute gastroenteritis in neonates and in-
fants in Vellore, India. J Clin Microbiol 2004; 42:2541–7.
17. Bhan MK, Lew JF, Sazawal S, Das BK, Gentsch JR, Glass RI. Protection
conferred by neonatal rotavirus infection against subsequent diarrhea.
J Infect Dis 1993; 168:282–7.
18. Ramachandran M, Das BK, Vij A, et al. Unusual diversity of human
rotavirus G and P genotypes in India. J Clin Microbiol 1996; 34:436–9.
19. Ramachandran M, Gentsch JR, Parashar UD, et al. Detection and
characterization of novel rotavirus strains in the United States. J Clin
Microbiol 1998; 36:3223–9.
20. Ramachandran M, Kirkwood CD, Unicomb L, et al. Molecular char-
acterization of serotype G9 rotavirus strains from a global collection.
Virology 2000; 278:436–44.
21. Laird AR, Gentsch JR, Nakagomi T, Nakagomi O, Glass RI. Charac-
terization of serotype G9 rotavirus strains isolated in the United States
and India from 1993 to 2001. J Clin Microbiol 2003; 41:3100–11.
22. Griffin DD, Kirkwood C, Parashar UD, et al. Surveillance of rotavirus
strains in the United States: identification of unusual strains. The Na-
tional Rotavirus Strain Surveillance System collaborating laboratories.
J Clin Microbiol 2000; 38:2784–7.
23. Vethanayagam R, Ananda B, Nagalaxmi M, et al. Possible role of neo-
natal infection by the asymptomatic reassortant strain I321 in the de-
cline in rotavirus diarrhea hospital admissions over a 12-year period
in Bangalore, India. J Infect Dis 2004; 189:2282–9.
